Efficacy and Safety of Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-09

Study Completion Date

2027-04-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to assess the efficacy and safety of fecal microbiota transplantation (FMT) for patients with irritable bowel syndrome (IBS). The main objectives of the study are:

To determine if FMT can significantly reduce IBS symptoms and improve patients' quality of life.

To evaluate any potential adverse effects associated with FMT in IBS patients. Researchers will compare outcomes in patients receiving FMT with a standard care protocol to gauge the effectiveness of FMT in alleviating IBS symptoms.

Participants will:

Receive FMT via endoscopic methods as per the study protocol. Attend scheduled clinic visits for assessments and symptom tracking over a 48-week period, with optional long-term follow-up for up to 3 years.

Complete regular questionnaires and microbiota assessments to monitor symptoms and gut health changes over time.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety Evaluation of Fecal Microbiota Transplantation in Irritable Bowel Syndrome

NCT05740319

Irritable Bowel Syndrome

UNKNOWN NA

Study of Fecal Microbiota Transplantation (FMT) in Severe IBS Patients

NCT06433180

Irritable Bowel Syndrome

NOT_YET_RECRUITING PHASE3

Effect of Fecal Microbiota Transplantation in Irritable Bowel Syndrome

NCT02788071

Irritable Bowel Syndrome

COMPLETED PHASE2/PHASE3

Donor Versus Autologous Fecal Microbiota Transplantation for Irritable Bowel Syndrome

NCT04691544

Irritable Bowel Syndrome

ACTIVE_NOT_RECRUITING PHASE3

Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome

NCT02092402

Irritable Bowel Syndrome (IBS)

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Irritable Bowel Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FMT

Fecal microbiota transplantation: fecal suspension delivered to duodenal 3rd portion via esophagogastroduodenoscopy

Group Type EXPERIMENTAL

Fecal Microbial Transplantation

Intervention Type OTHER

Fecal suspension is delivered to duodenal 3rd portion via esophagogastroduodenoscopy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fecal Microbial Transplantation

Fecal suspension is delivered to duodenal 3rd portion via esophagogastroduodenoscopy

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Korean men and women aged 19 to 80 years
2. Diagnosed according to Rome IV criteria, with abdominal pain occurring at least once per week that began more than 6 months prior and has recurred over the past 3 months, accompanied by at least two of the following symptoms: pain related to defecation, changes in stool frequency (increase or decrease), or changes in stool form (looser or harder consistency)
3. Patients with moderate to severe IBS (IBS-SSS score of 175 or higher) with diarrhea-predominant, mixed-type, or abdominal bloating as the main symptom, who have not responded to IBS medication therapy for over 3 months
4. Patients who have had a colonoscopy within the past 5 years, or those who will undergo a colonoscopy after joining the study, and for whom no structural abnormalities in the colon are identified (records from other hospitals within the past 5 years may be used). \*Patients who have undergone a biopsy or polypectomy during colonoscopy and can provide examination results are eligible if deemed appropriate by the clinician
5. Females who are surgically infertile or females of childbearing potential with a negative pregnancy test (urine hCG or serum b-hCG); females of childbearing potential or males who agree to use effective contraception (e.g., oral contraceptives, IUD, double-barrier methods, or hormonal implants) during the study period
6. Individuals capable of clearly expressing their intentions without significant neurological or psychiatric issues. Those with neurological or psychiatric conditions may participate if deemed stable with appropriate medication or other treatments
7. Patients who voluntarily provide written informed consent to participate in the study

Exclusion Criteria

1. Pregnant or breastfeeding women
2. Patients who have received investigational drugs within 3 months prior to Visit 1 (if investigational drugs were used within 3 months, consult the study monitor for case-by-case assessment)
3. Patients whom the investigator deems to be at risk or to have conditions that would interfere with participation in the clinical trial
4. Patients with severe congestive heart failure or severe angina
5. Patients diagnosed with lactose intolerance or those who are immunocompromised
6. Patients currently taking medications that may affect the study drug (e.g., intestinal drugs, probiotics), or those who need to continue these medications during the study period. Patients who are currently on these medications can participate after a 2-week washout period
7. Patients whose systolic blood pressure exceeds 160 mmHg or diastolic blood pressure exceeds 100 mmHg at Visit 1, with uncontrolled hypertension regardless of treatment status
8. Patients with uncontrolled endocrine disorders (e.g., diabetes), metabolic disorders (e.g., secondary hyperlipidemia), or hypothyroidism. Patients with a history of hypothyroidism may participate if they have been on a stable thyroid hormone replacement therapy for at least 4 weeks before Visit 2 and have a TSH level within the normal range at Visit 2
9. Patients with impaired renal function (creatinine \> 2.0 mg/dL) or nephrotic syndrome at Visit 1
10. Patients with a history of cancer within the last 5 years (except for those deemed cured)
11. Patients with significant psychiatric instability or psychiatric disorders not adequately controlled with medication or other treatment
12. Patients who have taken systemic steroid medications within 1 month prior to Visit 1
13. Patients who have undergone abdominal surgery other than appendectomy, cholecystectomy, cesarean section, hernia repair, or hysterectomy. \*Patients with other abdominal surgeries may still participate if deemed eligible by the investigator
14. Any other patient whom the investigator deems unsuitable for the study

Minimum Eligible Age

19 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No